Zimmer Biomet Holdings, Inc. (ZBH) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 a...
Zimmer Biomet Holdings, Inc. (ZBH) currently trades at a P/E ratio of 22.46 (historical range: 19.89–129.18, median: 48.87), placing it at the 14th percentile — cheap relative to its history, P/S ratio of 2.13 (range: 1.85–4.30, 7th percentile — cheap relative to its history), EV/EBITDA of 20.96 (range: 17.54–46.25, 31th percentile).
Over the historical period (2021-09-14 to 2026-10-16), Zimmer Biomet Holdings, Inc.'s P/E ratio has contracted by 41% over the observed period (from an average of 67.8 to 40.3).
Zimmer Biomet Holdings, Inc. trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 22.46 | 48.87 | 14th | cheap relative to its history |
| P/S Ratio | 2.13 | 3.19 | 7th | cheap relative to its history |
| EV/EBITDA | 20.96 | 33.76 | 31th | below its historical average |
| FCF Yield | 8.41% | 5.40% | 95th | cheap relative to its history |
Zimmer Biomet Holdings, Inc. (ZBH) Valuation & P/E History
Zimmer Biomet Holdings, Inc. (ZBH) is a US-listed stock operating in the Healthcare sector, specifically the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry currently trading at $94.25 with a market capitalization of $18.0 billion. This page provides historical valuation analysis for ZBH based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 22.46 is below the historical median of 48.87, placing ZBH at the 14th percentile of its valuation range. The P/S ratio of 2.13 compares to a median of 3.19.
ZBH Valuation Metrics & Historical Range
The valuation table above shows Zimmer Biomet Holdings, Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether ZBH is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests ZBH is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Zimmer Biomet Holdings, Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is ZBH Overvalued or Undervalued?
Zimmer Biomet Holdings, Inc. trades well below its historical valuation range across most metrics. The overall valuation percentile of 17 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive ZBH is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full ZBH analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.ZBH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.